Jove
Visualize
Contact Us

Related Experiment Videos

[Anticoagulation: the present and the future].

Ch Vetter1

  • 1Merkenicher Str. 224, 50735 Koln, Germany.

Hamostaseologie
|September 7, 2002
PubMed
Summary
This summary is machine-generated.

Direct oral thrombin inhibitors like ximelagatran offer an alternative to conventional anticoagulants. Ongoing clinical trials are evaluating the antithrombotic efficacy and safety of this promising compound.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Working under pressure].

Praxis·2008
Same author

[Pneumatosis cystoides intestinalis: a rare illness in adults].

Praxis·2007
Same author

[MRI-based diagnosis of an acute bilateral compartment syndrome].

Praxis·2007
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Context:

  • Thrombin plays a critical role in the coagulation cascade.
  • Conventional anticoagulants have limitations.
  • Direct oral thrombin inhibitors represent a novel therapeutic class.

Purpose:

  • To evaluate the antithrombotic efficacy of ximelagatran.
  • To assess the safety profile of ximelagatran.
  • To determine if ximelagatran meets the criteria for an ideal anticoagulant.

Summary:

  • Ximelagatran is a direct oral thrombin inhibitor designed to overcome limitations of existing anticoagulants.
  • Its central role in inhibiting thrombin makes it a key target for anticoagulant therapy.
  • A comprehensive clinical development program is underway to study its efficacy and safety.

Related Experiment Videos

Impact:

  • Ximelagatran has the potential to be an ideal anticoagulant.
  • This research may lead to improved antithrombotic treatments.
  • The findings will inform clinical practice regarding novel anticoagulant use.